SEARCH

SEARCH BY CITATION

References

  • Abou-Sleiman P. M., Muqit M. M. and Wood N. W. (2006) Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat. Rev. Neurosci. 7, 207219.
  • Alim M. A., Hossain M. S., Arima K., Takeda K., Izumiyama Y., Nakamura M., Kaji H., Shinoda T., Hisanaga S. and Ueda K. (2002) Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem. 277, 21122117.
  • Altschuler E. (1999) Aluminum-containing antacids as a cause of idiopathic Parkinson’s disease. Med. Hypotheses 53, 2223.
  • Arawaka S., Saito Y., Murayama S. and Mori H. (1998) Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 51, 887889.
  • Arima K., Ueda K., Sunohara N., Hirai S., Izumiyama Y., Tonozuka-Uehara H. and Kawai M. (1998a) Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson’s disease and in dementia with Lewy bodies. Brain Res. 808, 93100.
  • Arima K., Ueda K., Sunohara N., Arakawa K., Hirai S., Nakamura M., Tonozuka-Uehara H. and Kawai M. (1998b) NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol. (Berl.) 96, 439444.
  • Auluck P. K. and Bonini N. M. (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8, 11851186.
  • Auluck P. K., Chan H. Y., Trojanowski J. Q., Lee V. M. and Bonini N. M. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 295, 865868.
  • Baba M., Nakajo S., Tu P. H., Tomita T., Nakaya K., Lee V. M., Trojanowski J. Q. and Iwatsubo T. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879884.
  • Bayer T. A., Jakala P., Hartmann T., Havas L., McLean C., Culvenor J. G., Li Q. X., Masters C. L., Falkai P. and Beyreuther K. (1999) Alpha-synuclein accumulates in Lewy bodies in Parkinson’s disease and dementia with Lewy bodies but not in Alzheimer’s disease beta-amyloid plaque cores. Neurosci. Lett. 266, 213216.
  • Beal M. F. (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357366.
  • Bennett M. C. (2005) The role of alpha-synuclein in neurodegenerative diseases. Pharmacol. Ther. 105, 311331.
  • Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. and Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 3, 13011306.
  • Beyer K. (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. (Berl.) 112, 237251.
  • Binolfi A., Rasia R. M., Bertoncini C. W., Ceolin M., Zweckstetter M., Griesinger C., Jovin T. M. and Fernandez C. O. (2006) Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J. Am. Chem. Soc. 128, 98939901.
  • Bismuto E., Martelli P. L., De Maio A., Mita D. G., Irace G. and Casadio R. (2002) Effect of molecular confinement on internal enzyme dynamics: frequency domain fluorometry and molecular dynamics simulation studies. Biopolymers 67, 8595.
  • Bodles A. M., Guthrie D. J., Harriott P., Campbell P. and Irvine G. B. (2000) Toxicity of non-abeta component of Alzheimer’s disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur. J. Biochem. 267, 21862194.
  • Bodles A. M., Guthrie D. J., Greer B. and Irvine G. B. (2001) Identification of the region of non-Abeta component (NAC) of Alzheimer’s disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 78, 384395.
  • Bodner R. A., Housman D. E. and Kazantsev A. G. (2006a) New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions. Cell Cycle 5, 14771480.
  • Bodner R. A., Outeiro T. F., Altmann S., Maxwell M. M., Cho S. H., Hyman B. T., McLean P. J., Young A. B., Housman D. E. and Kazantsev A. G. (2006b) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington’s and Parkinson’s diseases. Proc. Natl Acad. Sci. USA 103, 42464251.
  • Bonini N. M. and Giasson B. I. (2005) Snaring the function of alpha-synuclein. Cell 123, 359361.
  • Braak H., Braak E., Yilmazer D., De Vos R. A., Jansen E. N., Bohl J. and Jellinger K. (1994) Amygdala pathology in Parkinson’s disease. Acta Neuropathol. (Berl.) 88, 493500.
  • Braak H., Sandmann-Keil D., Gai W. and Braak E. (1999) Extensive axonal Lewy neurites in Parkinson’s disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci. Lett. 265, 6769.
  • Bracken C., Iakoucheva L. M., Romero P. R. and Dunker A. K. (2004) Combining prediction, computation and experiment for the characterization of protein disorder. Curr. Opin. Struct. Biol. 14, 570576.
  • Bussell R. Jr and Eliezer D. (2001) Residual structure and dynamics in Parkinson’s disease-associated mutants of alpha-synuclein. J. Biol. Chem. 276, 4599646003.
  • Butterfield D. A. and Kanski J. (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 122, 945962.
  • Cappai R., Leck S. L., Tew D. J. et al. (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 19, 13771379.
  • Castagnet P. I., Golovko M. Y., Barcelo-Coblijn G. C., Nussbaum R. L. and Murphy E. J. (2005) Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. J. Neurochem. 94, 839849.
  • Chandra S., Chen X., Rizo J., Jahn R. and Sudhof T. C. (2003) A broken alpha-helix in folded alpha-synuclein. J. Biol. Chem. 278, 1531315318.
  • Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O. M. and Sudhof T. C. (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123, 383396.
  • Chen Y. G., Siddhanta A., Austin C. D., Hammond S. M., Sung T. C., Frohman M. A., Morris A. J. and Shields D. (1997) Phospholipase D stimulates release of nascent secretory vesicles from the trans-Golgi network. J. Cell Biol. 138, 495504.
  • Clayton D. F. and George J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249254.
  • Clayton D. F. and George J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120129.
  • Cohlberg J. A., Li J., Uversky V. N. and Fink A. L. (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 41, 15021511.
  • Cole N. B., Murphy D. D., Grider T., Rueter S., Brasaemle D. and Nussbaum R. L. (2002) Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein. J. Biol. Chem. 277, 63446352.
  • Conway K. A., Harper J. D. and Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 13181320.
  • Conway K. A., Harper J. D. and Lansbury P. T. Jr (2000a) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry 39, 25522563.
  • Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. and Lansbury P. T. Jr (2000b) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571576.
  • Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Harper J. D., Williamson R. E. and Lansbury P. T. Jr (2000c) Accelerated oligomerization by Parkinson’s disease linked alpha-synuclein mutants. Ann. NY Acad. Sci. 920, 4245.
  • Conway K. A., Rochet J. C., Bieganski R. M. and Lansbury P. T. Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 13461349.
  • Cookson M. R. (2005) The biochemistry of Parkinson’s disease. Annu. Rev. Biochem. 74, 2952.
  • Cookson M. R. (2006) Hero versus antihero: the multiple roles of alpha-synuclein in neurodegeneration. Exp. Neurol. 199, 238242.
  • Cooper A. A., Gitler A. D., Cashikar A. et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models. Science 313, 324328.
  • Crowther R. A., Jakes R., Spillantini M. G. and Goedert M. (1998) Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436, 309312.
  • Crowther R. A., Daniel S. E. and Goedert M. (2000) Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson’s disease brain. Neurosci. Lett. 292, 128130.
  • Dauer W. and Przedborski S. (2003) Parkinson’s disease: mechanisms and models. Neuron 39, 889909.
  • Daughdrill G. W., Pielak G. J., Uversky V. N., Cortese M. S. and Dunker A. K. (2005) Natively disordered proteins, in Handbook of Protein Folding (BuchnerJ. and KiefhaberT., eds.), pp. 271353. Wiley-VCH, Verlag GmbH & Co. KGaA, Weinheim, Germany.
  • Davidson W. S., Jonas A., Clayton D. F. and George J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 94439449.
  • Davis L. E. and Adair J. C. (1999) Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs. Mov. Disord. 14, 520522.
  • Dev K. K., Hofele K., Barbieri S., Buchman V. L. and Van Der Putten H. (2003) Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45, 1444.
  • Di Monte D. A. (2001) The role of environmental agents in Parkinson’s disease. Clin. Neurosci. Res. 1, 419426.
  • Di Monte D. A. (2003) The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2, 531538.
  • Di Monte D. A., Lavasani M. and Manning-Bog A. B. (2002) Environmental factors in Parkinson’s disease. Neurotoxicology 23, 487502.
  • Dickson D. W., Ruan D., Crystal H., Mark M. H., Davies P., Kress Y. and Yen S. H. (1991) Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 41, 14021409.
  • Ding T. T., Lee S. J., Rochet J. C. and Lansbury P. T. Jr (2002) Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 1020910217.
  • Dosztanyi Z., Csizmok V., Tompa P. and Simon I. (2005) IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 21, 34333434.
  • Duda J. E., Giasson B. I., Chen Q., Gur T. L., Hurtig H. I., Stern M. B., Gollomp S. M., Ischiropoulos H., Lee V. M. and Trojanowski J. Q. (2000) Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 157, 14391445.
  • Dunker A. K. and Obradovic Z. (2001) The protein trinity–linking function and disorder. Nat. Biotechnol. 19, 805806.
  • Dunker A. K., Lawson J. D., Brown C. J. et al. (2001) Intrinsically disordered protein. J. Mol. Graph. Model 19, 2659.
  • Dunker A. K., Brown C. J. and Obradovic Z. (2002a) Identification and functions of usefully disordered proteins. Adv. Protein Chem. 62, 2549.
  • Dunker A. K., Brown C. J., Lawson J. D., Iakoucheva L. M. and Obradovic Z. (2002b) Intrinsic disorder and protein function. Biochemistry 41, 65736582.
  • Dunker A. K., Cortese M. S., Romero P., Iakoucheva L. M. and Uversky V. N. (2005) Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J. 272, 51295148.
  • Dyson H. J. and Wright P. E. (2005) Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6, 197208.
  • Eggers D. K. and Valentine J. S. (2001a) Crowding and hydration effects on protein conformation: a study with sol-gel encapsulated proteins. J. Mol. Biol. 314, 911922.
  • Eggers D. K. and Valentine J. S. (2001b) Molecular confinement influences protein structure and enhances thermal protein stability. Protein Sci. 10, 250261.
  • El-Agnaf O. M., Jakes R., Curran M. D. and Wallace A. (1998a) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson’s disease. FEBS Lett. 440, 6770.
  • El-Agnaf O. M., Bodles A. M., Guthrie D. J., Harriott P. and Irvine G. B. (1998b) The N-terminal region of non-A beta component of Alzheimer’s disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur. J. Biochem. 258, 157163.
  • El-Agnaf O. M., Jakes R., Curran M. D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D. and Wallace A. (1998c) Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440, 7175.
  • Eliezer D., Kutluay E., Bussell R. Jr and Browne G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 10611073.
  • Ellis R. J. (2001) Macromolecular crowding: obvious but underappreciated. Trends Biochem. Sci. 26, 597604.
  • Eriksen J. L., Wszolek Z. and Petrucelli L. (2005) Molecular pathogenesis of Parkinson disease. Arch. Neurol. 62, 353357.
  • Fall P. A., Fredrikson M., Axelson O. and Granerus A. K. (1999) Nutritional and occupational factors influencing the risk of Parkinson’s disease: a case-control study in southeastern Sweden. Mov. Disord. 14, 2837.
  • Farrer M., Kachergus J., Forno L. et al. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55, 174179.
  • Fink A. L. (2005) Natively unfolded proteins. Curr. Opin. Struct. Biol. 15, 3541.
  • Forno L. S. (1996) Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55, 259272.
  • Fortin D. L., Troyer M. D., Nakamura K., Kubo S., Anthony M. D. and Edwards R. H. (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24, 67156723.
  • Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K. and Iwatsubo T. (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160164.
  • Fulton A. B. (1982) How crowded is the cytoplasm? Cell 30, 345347.
  • Furesz S. (1970) Chemical and biological properties of rifampicin. Antibiot. Chemother. 16, 316351.
  • Gai W. P., Power J. H., Blumbergs P. C. and Blessing W. W. (1998) Multiple-system atrophy: a new alpha-synuclein disease? Lancet 352, 547548.
  • Gai W. P., Power J. H., Blumbergs P. C., Culvenor J. G. and Jensen P. H. (1999) Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J. Neurochem. 73, 20932100.
  • Galat A. (2003) Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity–targets–functions. Curr. Top. Med. Chem. 3, 13151347.
  • Galpern W. R. and Lang A. E. (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann. Neurol. 59, 449458.
  • Galvin J. E., Lee V. M., Schmidt M. L., Tu P. H., Iwatsubo T. and Trojanowski J. Q. (1999) Pathobiology of the Lewy body. Adv. Neurol. 80, 313324.
  • Galvin J. E., Lee V. M. and Trojanowski J. Q. (2001) Synucleinopathies: clinical and pathological implications. Arch. Neurol. 58, 186190.
  • Gandhi S. and Wood N. W. (2005) Molecular pathogenesis of Parkinson’s disease. Hum. Mol. Genet. 14 Spec No. 2, 27492755.
  • Gao Z., Huang K. and Xu H. (2001) Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. Pharmacol. Res. 43, 173178.
  • George J. M., Jin H., Woods W. S. and Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361372.
  • Gerard M., Debyser Z., Desender L., Kahle P. J., Baert J., Baekelandt V. and Engelborghs Y. (2006) The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEB J. 20, 524526.
  • Giasson B. I., Uryu K., Trojanowski J. Q. and Lee V. M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 76197622.
  • Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I., Ischiropoulos H., Trojanowski J. Q. and Lee V. M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985989.
  • Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q. and Lee V. M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521533.
  • Glaser C. B., Yamin G., Uversky V. N. and Fink A. L. (2005) Methionine oxidation, alpha-synuclein and Parkinson’s disease. Biochim. Biophys. Acta 1703, 157169.
  • Goedert M. (1999) Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 11011118.
  • Goedert M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492501.
  • Goers J., Uversky V. N. and Fink A. L. (2003a) Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. Protein Sci. 12, 702707.
  • Goers J., Manning-Bog A. B., McCormack A. L., Millett I. S., Doniach S., Di Monte D. A., Uversky V. N. and Fink A. L. (2003b) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42, 84658471.
  • Goldberg M. S. and Lansbury P. T. Jr (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson’s disease? Nat. Cell Biol. 2, E115E119.
  • Golovko M. Y., Faergeman N. J., Cole N. B., Castagnet P. I., Nussbaum R. L. and Murphy E. J. (2005) Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Biochemistry 44, 82518259.
  • Golts N., Snyder H., Frasier M., Theisler C., Choi P. and Wolozin B. (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277, 1611616123.
  • Good P. F., Olanow C. W. and Perl D. P. (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson’s disease: a LAMMA study. Brain Res. 593, 343346.
  • Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L. and Richardson R. J. (1998) The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 50, 13461350.
  • Gorell J. M., Rybicki B. A., Johnson C. C. and Peterson E. L. (1999a) Occupational metal exposures and the risk of Parkinson’s disease. Neuroepidemiology 18, 303308.
  • Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Kortsha G. X., Brown G. G. and Richardson R. J. (1999b) Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson’s disease. Neurotoxicology 20, 239247.
  • Gosavi N., Lee H. J., Lee J. S., Patel S. and Lee S. J. (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277, 4898448992.
  • Greenbaum E. A., Graves C. L., Mishizen-Eberz A. J., Lupoli M. A., Lynch D. R., Englander S. W., Axelsen P. H. and Giasson B. I. (2005) The E46 K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 78007807.
  • Hageman G., Van Der Hoek J., Van Hout M., Van Der Laan G., Steur E. J., De Bruin W. and Herholz K. (1999) Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J. Neurol. 246, 198206.
  • Han H., Weinreb P. H. and Lansbury P. T. Jr (1995) The core Alzheimer’s peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem. Biol. 2, 163169.
  • Hashimoto M., Rockenstein E., Mante M., Mallory M. and Masliah E. (2001) Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213223.
  • Hernan M. A., Takkouche B., Caamano-Isorna F. and Gestal-Otero J. J. (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann. Neurol. 52, 276284.
  • Hertzman C., Wiens M., Snow B., Kelly S. and Calne D. (1994) A case-control study of Parkinson’s disease in a horticultural region of British Columbia. Mov. Disord. 9, 6975.
  • Hirsch E. C., Brandel J. P., Galle P., Javoy-Agid F. and Agid Y. (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J. Neurochem. 56, 446451.
  • Ho G. J., Gregory E. J., Smirnova I. V., Zoubine M. N. and Festoff B. W. (1994) Cross-linking of beta-amyloid protein precursor catalyzed by tissue transglutaminase. FEBS Lett. 349, 151154.
  • Hokenson M. J., Uversky V. N., Goers J., Yamin G., Munishkina L. A. and Fink A. L. (2004) Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein. Biochemistry 43, 46214633.
  • Ikezoe T., Chen S. S., Heber D., Taguchi H. and Koeffler H. P. (2001) Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 49, 285292.
  • Irizarry M. C., Growdon W., Gomez-Isla T., Newell K., George J. M., Clayton D. F. and Hyman B. T. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334337.
  • Ischiropoulos H. (1998) Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch. Biochem. Biophys. 356, 111.
  • Ischiropoulos H. (2003) Biological selectivity and functional aspects of protein tyrosine nitration. Biochem. Biophys. Res. Commun. 305, 776783.
  • Iwai A., Yoshimoto M., Masliah E. and Saitoh T. (1995a) Non-A beta component of Alzheimer’s disease amyloid (NAC) is amyloidogenic. Biochemistry 34, 1013910145.
  • Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., De Silva H. A., Kittel A. and Saitoh T. (1995b) The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467475.
  • Jao C. C., Der-Sarkissian A., Chen J. and Langen R. (2004) Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl Acad. Sci. USA 101, 83318336.
  • Jellinger K. A. (2003) Neuropathological spectrum of synucleinopathies. Mov. Disord. 18(Suppl. 6), S2S12.
  • Jenco J. M., Rawlingson A., Daniels B. and Morris A. J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37, 49014909.
  • Jensen P. H., Nielsen M. S., Jakes R., Dotti C. G. and Goedert M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson’s disease mutation. J. Biol. Chem. 273, 2629226294.
  • Jin J., Li G. J., Davis J., Zhu D., Wang Y., Pan C. and Zhang J. (2007) Identification of novel proteins interacting with both α-synuclein and DJ-1. Mol. Cell Proteomics 6, 845859.
  • Jo E., McLaurin J., Yip C. M., St George-Hyslop P. and Fraser P. E. (2000) Alpha-synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 3432834334.
  • Jo E., Darabie A. A., Han K., Tandon A., Fraser P. E. and McLaurin J. (2004) Alpha-synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. Eur. J. Biochem. 271, 31803189.
  • Junn E., Ronchetti R. D., Quezado M. M., Kim S. Y. and Mouradian M. M. (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson’s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 100, 20472052.
  • Kahle P. J., Neumann M., Ozmen L. et al. (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 3, 583588.
  • Kamp F. and Beyer K. (2006) Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. J. Biol. Chem. 281, 92519259.
  • Kim Y. S., Laurine E., Woods W. and Lee S. J. (2006) A novel mechanism of interaction between alpha-synuclein and biological membranes. J. Mol. Biol. 360, 386397.
  • Kisilevsky R. (2000) Review: amyloidogenesis-unquestioned answers and unanswered questions. J. Struct. Biol. 130, 99108.
  • Klawans H. L., Stein R. W., Tanner C. M. and Goetz C. G. (1982) A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch. Neurol. 39, 302304.
  • Ko L., Mehta N. D., Farrer M., Easson C., Hussey J., Yen S., Hardy J. and Yen S. H. (2000) Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J. Neurochem. 75, 25462554.
  • Kowall N. W., Hantraye P., Brouillet E., Beal M. F., McKee A. C. and Ferrante R. J. (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211213.
  • Krishnan S., Chi E. Y., Wood S. J. et al. (2003) Oxidative dimer formation is the critical rate-limiting step for Parkinson’s disease alpha-synuclein fibrillogenesis. Biochemistry 42, 829837.
  • Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 18, 106108.
  • Langston J. W. and Ballard P. A. Jr (1983) Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 309, 310.
  • Lansbury P. T. Jr (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc. Natl Acad. Sci. USA 96, 33423344.
  • Larsen K. E., Schmitz Y., Troyer M. D. et al. (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 26, 1191511922.
  • Lashuel H. A., Hartley D., Petre B. M., Walz T. and Lansbury P. T. Jr (2002a) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
  • Lashuel H. A., Petre B. M., Wall J., Simon M., Nowak R. J., Walz T. and Lansbury P. T. Jr (2002b) Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 10891102.
  • De Laureto P. P., Tosatto L., Frare E., Marin O., Uversky V. N. and Fontana A. (2006) Conformational properties of the SDS-bound state of alpha-synuclein probed by limited proteolysis: unexpected rigidity of the acidic C-terminal tail. Biochemistry 45, 1152311531.
  • Lavedan C. (1998) The synuclein family. Genome Res. 8, 871880.
  • Lee H. J., Choi C. and Lee S. J. (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671678.
  • Lesort M., Chun W., Johnson G. V. and Ferrante R. J. (1999) Tissue transglutaminase is increased in Huntington’s disease brain. J. Neurochem. 73, 20182027.
  • Levine R. L., Mosoni L., Berlett B. S. and Stadtman E. R. (1996) Methionine residues as endogenous antioxidants in proteins. Proc. Natl Acad. Sci. USA 93, 1503615040.
  • Li X., Romero P., Rani M., Dunker A. K. and Obradovic Z. (1999) Predicting protein disorder for N-, C-, and internal regions. Genome Inform. Ser Workshop Genome Inform. 10, 3040.
  • Li B. Q., Fu T., Gong W. H., Dunlop N., Kung H., Yan Y., Kang J. and Wang J. M. (2000) The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. Immunopharmacology 49, 295306.
  • Li J., Uversky V. N. and Fink A. L. (2001) Effect of familial Parkinson’s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 1160411613.
  • Li J., Uversky V. N. and Fink A. L. (2002) Conformational behavior of human alpha-synuclein is modulated by familial Parkinson’s disease point mutations A30P and A53T. Neurotoxicology 23, 553567.
  • Li J., Zhu M., Manning-Bog A. B., Di Monte D. A. and Fink A. L. (2004a) Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson’s and Alzheimer’s disease. FASEB J. 18, 962964.
  • Li J., Zhu M., Rajamani S., Uversky V. N. and Fink A. L. (2004b) Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem. Biol. 11, 15131521.
  • Lindersson E. and Jensen P. H. (2004) Alpha-synuclein binding proteins, in Molecular Mechanisms of Parkinson’s Disease (KahleP. J. and HaassC., eds.), pp. 1–12. Landes Bioscience, Georgetown.
  • Lindersson E. K., Hojrup P., Gai W. P., Locker D., Martin D. and Jensen P. H. (2004) Alpha-synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport 15, 27352739.
  • Lindersson E., Lundvig D., Petersen C. et al. (2005) p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J. Biol. Chem. 280, 57035715.
  • Liou H. H., Tsai M. C., Chen C. J., Jeng J. S., Chang Y. C., Chen S. Y. and Chen R. C. (1997) Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 48, 15831588.
  • Litvan I., Halliday G., Hallett M. et al. (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J. Neuropathol. Exp. Neurol. 66, 251257.
  • Liu I. H., Uversky V. N., Munishkina L. A., Fink A. L., Halfter W. and Cole G. J. (2005) Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology 15, 13201331.
  • Lo Bianco C., Ridet J. L., Schneider B. L., Deglon N. and Aebischer P. (2002) Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 99, 1081310818.
  • Lowe R., Pountney D. L., Jensen P. H., Gai W. P. and Voelcker N. H. (2004) Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci. 13, 32453252.
  • Lucking C. B. and Brice A. (2000) Alpha-synuclein and Parkinson’s disease. Cell Mol. Life Sci. 57, 18941908.
  • Lundvig D., Lindersson E. and Jensen P. H. (2005) Pathogenic effects of alpha-synuclein aggregation. Brain Res. Mol. Brain Res. 134, 317.
  • Madine J., Doig A. J. and Middleton D. A. (2006) A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Biochemistry 45, 57835792.
  • Maguire-Zeiss K. A. and Federoff H. J. (2003) Convergent pathobiologic model of Parkinson’s disease. Ann. NY Acad. Sci. 991, 152166.
  • Maguire-Zeiss K. A., Short D. W. and Federoff H. J. (2005) Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson’s disease? Brain Res. Mol. Brain Res. 134, 1823.
  • Manning-Bog A. B., McCormack A. L., Li J., Uversky V. N., Fink A. L. and Di Monte D. A. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277, 16411644.
  • Maroteaux L., Campanelli J. T. and Scheller R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 28042815.
  • Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 12651269.
  • McCormack A. L., Thiruchelvam M., Manning-Bog A. B., Thiffault C., Langston J. W., Cory-Slechta D. A. and Di Monte D. A. (2002) Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10, 119127.
  • McLaurin J., Yang D., Yip C. M. and Fraser P. E. (2000) Review: modulating factors in amyloid-beta fibril formation. J. Struct. Biol. 130, 259270.
  • McLean P. J., Kawamata H., Ribich S. and Hyman B. T. (2000) Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson’s disease-linked mutations. J. Biol. Chem. 275, 88128816.
  • McLean P. J., Kawamata H., Shariff S., Hewett J., Sharma N., Ueda K., Breakefield X. O. and Hyman B. T. (2002) TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J. Neurochem. 83, 846854.
  • McNulty B. C., Young G. B. and Pielak G. J. (2006) Macromolecular crowding in the Escherichia coli periplasm maintains alpha-synuclein disorder. J. Mol. Biol. 355, 893897.
  • Miller M. L. and Johnson G. V. (1995) Transglutaminase cross-linking of the tau protein. J. Neurochem. 65, 17601770.
  • Miller D. W., Hague S. M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M. R. and Singleton A. B. (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62, 18351838.
  • Minton A. P. (2000a) Effect of a concentrated ‘inert’ macromolecular cosolute on the stability of a globular protein with respect to denaturation by heat and by chaotropes: a statistical-thermodynamic model. Biophys. J. 78, 101109.
  • Minton A. P. (2000b) Implications of macromolecular crowding for protein assembly. Curr. Opin. Struct. Biol. 10, 3439.
  • Minton A. P. (2001) The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J. Biol. Chem. 276, 1057710580.
  • Moore D. J., West A. B., Dawson V. L. and Dawson T. M. (2005) Molecular pathophysiology of Parkinson’s disease. Annu. Rev. Neurosci. 28, 5787.
  • Morar A. S., Olteanu A., Young G. B. and Pielak G. J. (2001) Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c. Protein Sci. 10, 21952199.
  • Morris H. R. (2005) Genetics of Parkinson’s disease. Ann. Med. 37, 8696.
  • Moskovitz J., Jenkins N. A., Gilbert D. J., Copeland N. G., Jursky F., Weissbach H. and Brot N. (1996) Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. Proc. Natl Acad. Sci. USA 93, 32053208.
  • Mukaetova-Ladinska E. B. and McKeith I. G. (2006) Pathophysiology of synuclein aggregation in Lewy body disease. Mech. Ageing Dev. 127, 188202.
  • Munishkina L. A., Phelan C., Uversky V. N. and Fink A. L. (2003) Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes. Biochemistry 42, 27202730.
  • Munishkina L. A., Henriques J., Uversky V. N. and Fink A. L. (2004) Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. Biochemistry 43, 32893300.
  • Murray I. V., Giasson B. I., Quinn S. M., Koppaka V., Axelsen P. H., Ischiropoulos H., Trojanowski J. Q. and Lee V. M. (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 85308540.
  • Narayanan V. and Scarlata S. (2001) Membrane binding and self-association of alpha-synucleins. Biochemistry 40, 99279934.
  • Narhi L., Wood S. J., Steavenson S. et al. (1999) Both familial Parkinson’s disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 98439846.
  • Necula M., Chirita C. N. and Kuret J. (2003) Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. J. Biol. Chem. 278, 4667446680.
  • Neumann M., Kahle P. J., Giasson B. I. et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110, 14291439.
  • Nielsen M. S., Vorum H., Lindersson E. and Jensen P. H. (2001) Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J. Biol. Chem. 276, 2268022684.
  • Nishie M., Mori F., Yoshimoto M., Takahashi H. and Wakabayashi K. (2004a) A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathol. Appl. Neurobiol. 30, 546554.
  • Nishie M., Mori F., Fujiwara H., Hasegawa M., Yoshimoto M., Iwatsubo T., Takahashi H. and Wakabayashi K. (2004b) Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. (Berl.) 107, 292298.
  • Obradovic Z., Peng K., Vucetic S., Radivojac P. and Dunker A. K. (2005) Exploiting heterogeneous sequence properties improves prediction of protein disorder. Proteins 61(Suppl. 7), 176182.
  • Ohlson C. G. and Hogstedt C. (1981) Parkinson’s disease and occupational exposure to organic solvents, agricultural chemicals and mercury–a case-referent study. Scand. J. Work Environ. Health 7, 252256.
  • Okazaki H., Lipkin L. E. and Aronson S. M. (1961) Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J. Neuropathol. Exp. Neurol. 20, 237244.
  • Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., Meijer L., Kahle P. J. and Haass C. (2000) Constitutive phosphorylation of the Parkinson’s disease associated alpha-synuclein. J. Biol. Chem. 275, 390397.
  • Outeiro T. F. and Lindquist S. (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 17721775.
  • Paik S. R., Lee J. H., Kim D. H., Chang C. S. and Kim J. (1997) Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer’s disease amyloid. Arch. Biochem. Biophys. 344, 325334.
  • Paik S. R., Shin H. J., Lee J. H., Chang C. S. and Kim J. (1999) Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J. 340, 821828.
  • Paik S. R., Shin H. J. and Lee J. H. (2000) Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch. Biochem. Biophys. 378, 269277.
  • Papp M. I., Kahn J. E. and Lantos P. L. (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 94, 79100.
  • Paxinou E., Chen Q., Weisse M., Giasson B. I., Norris E. H., Rueter S. M., Trojanowski J. Q., Lee V. M. and Ischiropoulos H. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 80538061.
  • Perrin R. J., Woods W. S., Clayton D. F. and George J. M. (2000) Interaction of human alpha-synuclein and Parkinson’s disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275, 3439334398.
  • Perrin R. J., Woods W. S., Clayton D. F. and George J. M. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276, 4195841962.
  • Pezzoli G., Strada O., Silani V. et al. (1996) Clinical and pathological features in hydrocarbon-induced parkinsonism. Ann. Neurol. 40, 922925.
  • Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276, 20452047.
  • Pountney D. L., Lowe R., Quilty M., Vickers J. C., Voelcker N. H. and Gai W. P. (2004) Annular alpha-synuclein species from purified multiple system atrophy inclusions. J. Neurochem. 90, 502512.
  • Pountney D. L., Treweek T. M., Chataway T., Huang Y., Chegini F., Blumbergs P. C., Raftery M. J. and Gai W. P. (2005) Alpha B-crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy. Neurotox. Res. 7, 7785.
  • Pronin A. N., Morris A. J., Surguchov A. and Benovic J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 2651526522.
  • Van Der Putten H., Wiederhold K. H., Probst A. et al. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 60216029.
  • Ramakrishnan M., Jensen P. H. and Marsh D. (2003) Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels. Biochemistry 42, 1291912926.
  • Rekas A., Adda C. G., Andrew Aquilina J. et al. (2004) Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J. Mol. Biol. 340, 11671183.
  • Romero P., Obradovic Z., Li X., Garner E. C., Brown C. J. and Dunker A. K. (2001) Sequence complexity of disordered protein. Proteins 42, 3848.
  • Romero P., Obradovic Z. and Dunker A. K. (2004) Natively disordered proteins : functions and predictions. Appl. Bioinformatics 3, 105113.
  • Saito Y., Kawashima A., Ruberu N. N. et al. (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J. Neuropathol. Exp. Neurol. 62, 644654.
  • Scherzer C. R., Jensen R. V., Gullans S. R. and Feany M. B. (2003) Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson’s disease. Hum. Mol. Genet. 12, 24572466.
  • Seidler A., Hellenbrand W., Robra B. P., Vieregge P., Nischan P., Joerg J., Oertel W. H., Ulm G. and Schneider E. (1996) Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology 46, 12751284.
  • Selkoe D. J., Abraham C. and Ihara Y. (1982) Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. Proc. Natl Acad. Sci. USA 79, 60706074.
  • Semchuk K. M., Love E. J. and Lee R. G. (1992) Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 42, 13281335.
  • Semchuk K. M., Love E. J. and Lee R. G. (1993) Parkinson’s disease: a test of the multifactorial etiologic hypothesis. Neurology 43, 11731180.
  • Serpell L. C., Berriman J., Jakes R., Goedert M. and Crowther R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl Acad. Sci. USA 97, 48974902.
  • Sharon R., Bar-Joseph I., Mirick G. E., Serhan C. N. and Selkoe D. J. (2003a) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J. Biol. Chem. 278, 4987449881.
  • Sharon R., Bar-Joseph I., Frosch M. P., Walsh D. M., Hamilton J. A. and Selkoe D. J. (2003b) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 37, 583595.
  • Shashidharan P., Kramer B. C., Walker R. H., Olanow C. W. and Brin M. F. (2000a) Immunohistochemical localization and distribution of torsinA in normal human and rat brain. Brain Res. 853, 197206.
  • Shashidharan P., Good P. F., Hsu A., Perl D. P., Brin M. F. and Olanow C. W. (2000b) TorsinA accumulation in Lewy bodies in sporadic Parkinson’s disease. Brain Res. 877, 379381.
  • Sherer T. B., Kim J. H., Betarbet R. and Greenamyre J. T. (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179, 916.
  • Shieh D. E., Liu L. T. and Lin C. C. (2000) Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 20, 28612865.
  • Shtilerman M. D., Ding T. T. and Lansbury P. T. Jr (2002) Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson’s disease? Biochemistry 41, 38553860.
  • Singleton A. B., Farrer M., Johnson J. et al. (2003) Alpha-synuclein locus triplication causes Parkinson’s disease. Science 302, 841.
  • Singleton A., Gwinn-Hardy K., Sharabi Y., Li S. T., Holmes C., Dendi R., Hardy J., Crawley A. and Goldstein D. S. (2004) Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 127, 768772.
  • Souza J. M., Giasson B. I., Chen Q., Lee V. M. and Ischiropoulos H. (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 1834418349.
  • Spillantini M. G. and Goedert M. (2000) The alpha-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Ann. NY Acad. Sci. 920, 1627.
  • Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839840.
  • Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. and Goedert M. (1998a) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 64696473.
  • Spillantini M. G., Crowther R. A., Jakes R., Cairns N. J., Lantos P. L. and Goedert M. (1998b) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205208.
  • Stadtman E. R. (1993) Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu. Rev. Biochem. 62, 797821.
  • Sun H., Gao J., Ferrington D. A., Biesiada H., Williams T. D. and Squier T. C. (1999) Repair of oxidized calmodulin by methionine sulfoxide reductase restores ability to activate the plasma membrane Ca-ATPase. Biochemistry 38, 105112.
  • Syme C. D., Blanch E. W., Holt C., Jakes R., Goedert M., Hecht L. and Barron L. D. (2002) A Raman optical activity study of rheomorphism in caseins, synucleins and tau. New insight into the structure and behaviour of natively unfolded proteins. Eur. J. Biochem. 269, 148156.
  • Takahashi M., Kanuka H., Fujiwara H., Koyama A., Hasegawa M., Miura M. and Iwatsubo T. (2003) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci. Lett. 336, 155158.
  • Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L. and Masliah E. (1998) Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol. 152, 367372.
  • Takeda A., Hashimoto M., Mallory M., Sundsumo M., Hansen L. and Masliah E. (2000) C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol. (Berl.) 99, 296304.
  • Talpade D. J., Greene J. G., Higgins D. S.,. Jr and Greenamyre J. T. (2000) In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J. Neurochem. 75, 26112621.
  • Tamamizu-Kato S., Kosaraju M. G., Kato H., Raussens V., Ruysschaert J. M. and Narayanaswami V. (2006) Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. Biochemistry 45, 1094710956.
  • Tanner C. M. (1989) The role of environmental toxins in the etiology of Parkinson’s disease. Trends Neurosci. 12, 4954.
  • Tanner C. M. and Aston D. A. (2000) Epidemiology of Parkinson’s disease and akinetic syndromes. Curr. Opin. Neurol. 13, 427430.
  • Tanner C. M., Chen B., Wang W., Peng M., Liu Z., Liang X., Kao L. C., Gilley D. W., Goetz C. G. and Schoenberg B. S. (1989) Environmental factors and Parkinson’s disease: a case-control study in China. Neurology 39, 660664.
  • Tofaris G. K. and Spillantini M. G. (2005) Alpha-synuclein dysfunction in Lewy body diseases. Mov. Disord. 20(Suppl. 12), S37S44.
  • Tompa P. (2002) Intrinsically unstructured proteins. Trends Biochem. Sci. 27, 527533.
  • Tompa P. (2005) The interplay between structure and function in intrinsically unstructured proteins. FEBS Lett. 579, 33463354.
  • Tompa P. and Csermely P. (2004) The role of structural disorder in the function of RNA and protein chaperones. FASEB J. 18, 11691175.
  • Tompa P., Szasz C. and Buday L. (2005) Structural disorder throws new light on moonlighting. Trends Biochem. Sci. 30, 484489.
  • Trojanowski J. Q. and Lee V. M. (2003) Parkinson’s disease and related alpha-synucleinopathies are brain amyloidoses. Ann. NY Acad. Sci. 991, 107110.
  • Trojanowski J. Q., Goedert M., Iwatsubo T. and Lee V. M. (1998) Fatal attractions: abnormal protein aggregation and neuron death in Parkinson’s disease and Lewy body dementia. Cell Death Differ. 5, 832837.
  • Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D. A., Kondo J., Ihara Y. and Saitoh T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1128211286.
  • Uitti R. J., Snow B. J., Shinotoh H., Vingerhoets F. J., Hayward M., Hashimoto S., Richmond J., Markey S. P., Markey C. J. and Calne D. B. (1994) Parkinsonism induced by solvent abuse. Ann. Neurol. 35, 616619.
  • Ulmer T. S., Bax A., Cole N. B. and Nussbaum R. L. (2005) Structure and dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem. 280, 95959603.
  • Uversky V. N. (2002a) Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 11, 739756.
  • Uversky V. N. (2002b) What does it mean to be natively unfolded? Eur. J. Biochem. 269, 212.
  • Uversky V. N. (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21, 211234.
  • Uversky V. N. (2004) Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 318, 225241.
  • Uversky V. N., Gillespie J. R. and Fink A. L. (2000) Why are ‘natively unfolded’ proteins unstructured under physiologic conditions? Proteins 41, 415427.
  • Uversky V. N., Li J. and Fink A. L. (2001a) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 1073710744.
  • Uversky V. N., Li J. and Fink A. L. (2001b) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J. Biol. Chem. 276, 4428444296.
  • Uversky V. N., Li J. and Fink A. L. (2001c) Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson’s disease. FEBS Lett. 500, 105108.
  • Uversky V. N., Li J. and Fink A. L. (2001d) Trimethylamine-N-oxide-induced folding of alpha-synuclein. FEBS Lett. 509, 3135.
  • Uversky V. N., Lee H. J., Li J., Fink A. L. and Lee S. J. (2001e) Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem. 276, 4349543498.
  • Uversky V. N., Li J., Bower K. and Fink A. L. (2002a) Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson’s disease. Neurotoxicology 23, 527536.
  • Uversky V. N., E M. C., Bower K. S., Li J. and Fink A. L. (2002b) Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett. 515, 99103.
  • Uversky V. N., Yamin G., Souillac P. O., Goers J., Glaser C. B. and Fink A. L. (2002c) Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 517, 239244.
  • Uversky V. N., Li J., Souillac P., Millett I. S., Doniach S., Jakes R., Goedert M. and Fink A. L. (2002d) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem. 277, 1197011978.
  • Uversky V. N., Oldfield C. J. and Dunker A. K. (2005a) Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J. Mol. Recognit. 18, 343384.
  • Uversky V. N., Yamin G., Munishkina L. A., Karymov M. A., Millett I. S., Doniach S., Lyubchenko Y. L. and Fink A. L. (2005b) Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res. Mol. Brain Res. 134, 84102.
  • Vanacore N., Nappo A., Gentile M. et al. (2002) Evaluation of risk of Parkinson’s disease in a cohort of licensed pesticide users. Neurol. Sci. 23(Suppl. 2), S119S120.
  • Vila M. and Przedborski S. (2004) Genetic clues to the pathogenesis of Parkinson’s disease. Nat. Med. 10(Suppl.), S58S62.
  • Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M. and Przedborski S. (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74, 721729.
  • Vogt W. (1995) Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic. Biol. Med. 18, 93105.
  • Volles M. J. and Lansbury P. T. Jr (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson’s disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 45954602.
  • Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M. and Takahashi H. (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson’s disease. Neurosci. Lett. 239, 4548.
  • Wakabayashi K., Yoshimoto M., Tsuji S. and Takahashi H. (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249, 180182.
  • Walker R. H., Brin M. F., Sandu D., Gujjari P., Hof P. R., Warren Olanow C. and Shashidharan P. (2001) Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain. Brain Res. 900, 348354.
  • Weinreb P. H., Zhen W., Poon A. W., Conway K. A. and Lansbury P. T. Jr (1996) NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35, 1370913715.
  • Willingham S., Outeiro T. F., DeVit M. J., Lindquist S. L. and Muchowski P. J. (2003) Yeast genes that enhance the toxicity of a mutant Huntingtin fragment or alpha-synuclein. Science 302, 17691772.
  • Wolozin B. and Golts N. (2002) Iron and Parkinson’s disease. Neuroscientist 8, 2232.
  • Wright P. E. and Dyson H. J. (1999) Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 293, 321331.
  • Wu J. A., Attele A. S., Zhang L. and Yuan C. S. (2001) Anti-HIV activity of medicinal herbs: usage and potential development. Am. J. Chin. Med. 29, 6981.
  • Xu J., Kao S. Y., Lee F. J., Song W., Jin L. W. and Yankner B. A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600606.
  • Yamin G., Uversky V. N. and Fink A. L. (2003a) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 542, 147152.
  • Yamin G., Glaser C. B., Uversky V. N. and Fink A. L. (2003b) Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J. Biol. Chem. 278, 2763027635.
  • Yamin G., Munishkina L. A., Karymov M. A., Lyubchenko Y. L., Uversky V. N. and Fink A. L. (2005) Forcing non-amyloidogenic β-synuclein to fibrillate. Biochemistry 44, 90969107.
  • Yancey P. H., Clark M. E., Hand S. C., Bowlus R. D. and Somero G. N. (1982) Living with water stress: evolution of osmolyte systems. Science 217, 12141222.
  • Yang Z. R., Thomson R., McNeil P. and Esnouf R. M. (2005) RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteins. Bioinformatics 21, 33693376.
  • Yasui M., Kihira T. and Ota K. (1992) Calcium, magnesium and aluminum concentrations in Parkinson’s disease. Neurotoxicology 13, 593600.
  • Zarranz J. J., Alegre J., Gomez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164173.
  • Zhou W., Hurlbert M. S., Schaack J., Prasad K. N. and Freed C. R. (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866, 3343.
  • Zhu M. and Fink A. L. (2003) Lipid binding inhibits alpha-synuclein fibril formation. J. Biol. Chem. 278, 1687316877.
  • Zhu M., Li J. and Fink A. L. (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J. Biol. Chem. 278, 4018640197.
  • Zhu M., Rajamani S., Kaylor J., Han S., Zhou F. and Fink A. L. (2004) The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279, 2684626857.
  • Zhu M., Qin Z. J., Hu D., Munishkina L. A. and Fink A. L. (2006) Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochemistry 45, 81358142.
  • Zimmerman S. B. and Trach S. O. (1991) Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. J. Mol. Biol. 222, 599620.